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A b s t r a c t  
Background. The dose available at the mouth from a pressurised metered-dose inhaler (pMDI) 
cannot stay the same if it is used with a valved holding chamber (VHC). A different aerosol drug 
delivery system is created when the pMDI is used with the VHC and therefore the dose delivered to 
the patients is no longer that released from the pMDI alone, but the one emitted by the new system. 
This study aims to verify the emitted dose of five pMDI drugs when used with a VHC.  
Methods. The emitted dose was expressed as the amount of drug within the respirable fraction 
available at the end of the VHC, i.e. the drug output (measured by high performance liquid 
chromatography) multiplied by the percentage of FDF determined using a laser diffraction analyser. 
Results. the emitted doses were drastically reduced in comparison with the nominal doses 
(Beclomethasone from 250 to 90.5 µg, Budesonide from 200 to 100 µg, Ciclesonide from 160 to 102 
µg Fluticasone from 250 to 116 µg, Salbutamol from 100 to 54 µg). 
Conclusions. When pMDIs are employed with a VHC, the emitted dose drastically changes; it is 
more or less halved. In order to facilitate prescription by the physician, both the nominal and the 
emitted doses should be reported in the VHC package. 
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Introduction 
Drugs for the treatment of asthma and asthma-like symptoms are 
frequently delivered from a pressurized metered dose inhaler 
(pMDI) used alone or with a spacer device. It has been reported 
that the pMDI effect is spacer-device dependent. [1] A valved 
holding chamber (VHC) decreases ballistic drug deposition in the 
oropharynx reducing the total body dose by 75%, improves the 
lower respiratory tract drug delivery efficiency of small aerosol 
particles by 30-50%, increases the therapeutic ratio, and facilitates 
patient and task specific aerosol delivery,[2]  
Aerosol therapy is a complex process dependent on aerosol drug 
delivery system (ADDS) performance and patients’ features. In 
order to avoid errors, these variables should be studied separately. 
[3] In the case of pMDIs, ADDS performance can be expressed as 
the amount of drug contained in an actuation (nominal dose). It is 
known that a different ADDS is created when the pMDI is used with 
a VHC; the dose available at the mouth is no longer that released 
from the pMDI alone, but the one emitted by the new system. In 
this case, the delivered dose is the fine particle dose (FPD), an 
objective parameter by which to quantify the amount of drug within 
the respirable range available at the end of the pMDI-VHC system 
[4] and potentially capable of reaching the lower airways. This 
mechanical method has been suggested in order to standardize 
first-step aerosol therapy. [5] Many studies have evaluated the 
effect of different VHCs for the delivery of single drugs using 
sampling mechanical methods reflecting different patient 
techniques. [6-9] In fact, the emitted dose is calculated using 
mechanical filters that change the resistance of airflow rather then 
respecting the breathing pattern of the patients. Furthermore, the 
emitted doses of different drugs at the end of the pMDI-VHC is 
never reported in the “Summaries of Product characteristics” and 
“Patient information Leaflets” of any VHC. 
The aim of this study was to verify this difference in the emitted 
dose by comparing the five most frequently used pMDI drugs when 
delivered without and with a VHC. 
Materials and methods 
The five pMDI drugs currently available on the market, namely 
Beclomethasone, Budesonide, Ciclesonide, Fluticasone and 
Salbutamol, were analyzed when used with a VHC (L’Espace, Air 
Liquide, Bovezzo Bs, Italy). This VHC with mouthpiece is declared 
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universally compatible with  the pMDIs. It has a polycarbonate 
chamber, and silicone valves, masks and MDI inlet. The plastic 
used has very low electrostatic properties. The chamber volume is 
220 cc and its dimensions are 6x6x15cm. 
Puff concentration, excipients and the same drug available in 
solution form used for high performance liquid chromatography 
(HPLC) reference are reported in Table I. All pMDIs employed 
hydrofluoroalkane as the propellent and were therefore 
chlorofluorocarbon free. 
Fine particle fraction (FPF): a laser diffraction analyzer (particle 
size distribution analyzer model 3603 produced by TSI and 
validated by Air Liquide Medical Systems compared to cascade 
impactor as requested by UNI EN 13544-1:2009) was used to 
determine the aerosol particle-size distribution, [10]  i.e. the fraction 
of aerosol capable of entering and remaining in the lung was 
calculated. The particle-size distribution was used to calculate the 
respirable fraction as the fraction of the volume of aerosol 
contained in particles of 1 - 4.6 mm in diameter. [11] 
Subjects. Five patients (4 males, 1 female, mean age 50.4 ± 11.7 
years); with normal spirometric values (exclusion criteria: previous 
treatment with selected pMDI drugs), were invited to take their 
treatment in our laboratory three times consecutively. The 
concentration of drug residual assay in the VHC was determined 
immediately after treatment in duplicate by HPLC. 
Sample collection. The patient was given the selected pMDI 
attached to the VHC and told to press the device and to inhale 
three times, consecutively. The chamber was then thoroughly 
washed with the elution mixture and brought to 20 mL. 
HPLC analysis. The chromatography equipment consisted of a 
2996 diode array detector and a 600 E Multisolvent Delivery 
system (Waters, Milford Massachusetts, USA) equipped with a 20 
μL loop. The chromatographic system was controlled by the 
Empower Pro software (Waters). The column was a Geminy-NX, 
4,6 x 250 mm, with 5 µm pore size and 110 Å particle size 
(Phenomenex, Torrance, USA) protected by a guard cartridge from 
the same package. Four drugs were assessed using a 10 min 
isocratic elution, with different percentages of methanol in water, 
and different flow rates, except that in the case of Salbutamol, 
where a gradient elution was applied, starting with a 50% of A and 
B, mantaining it for 4 min, then linearly increasing solvent B to 
100% during the following 4 min.       
A calibration curve was obtained for different amounts of 
commercial drugs in solution depending on the reported values of 
concentration, which were taken to be exact; in the case of 
Ciclesonide, no commercial solution was at hand, so a solution 
was prepared by puffing directly into a suitable amount of solvent. 
All samples were filtered through Waters HA 0.45 mm filters before 
injection.  
Results  
The elution conditions used in the HPLC analysis were derived in 
part from the paper of Steckel and Mőller. [12] Owing to the fact that 
only one drug at a time had to be measured, the amount of each 
compound was easily determined using the same column, using 
different eluent composition and flow rate at the wavelength of 
maximum absorption, as reported in Table II. 
Measured values were highly reproducible, obeying a linear law 
with a R2 always higher then 0.998 and with a good limit of 
quantification (LOQ), namely of 1.1, 0.9, 1.6, 0.54, and 1.3 mg/L for 
Beclomethasone, Budesonide, Ciclesonide, Fluticasone and 
Salbutamol, respectively. 
Table III shows the FPD available at the end of the VHC; this 
represents the emitted dose according to the formula described by 
Malone [4] and summarizes the comparison of the emitted dose of 
the drugs delivered by pMDI with or without the VHC. 
Discussion 
pMDI and VHC should be considered a single ADDS, since the 
emitted dose is no longer that released from the pMDI alone, but 
the one emitted by the new system.  
Our data confirmed that, when pMDIs are employed with a VHC, 
the emitted dose changes; [13-17]  it is more or less halved (36-
74%). This shows that VHC characteristics interfere drastically with 
pMDI drug delivery, as already reported. [18]  On the basis of this 
evidence, many patients probably do not use VHC-pMDI drugs 
properly and do not receive the optimal therapeutic dose. [19] EMA 
guidelines recommend that the development of a pMDI should 
always include testing of at least one specific spacer for use with a 
particular pMDI. [20] In fact, some pMDIs are licensed with a 
specific spacer. We agree that if a pMDI has been designed for use 
with a specific spacer it should always be used with this named 
spacing device. However, in this case both should be present in 
the same package to avoid misuse and this must also be reported 
in the product warnings: “these instructions are not necessarily 
valid when this pMDI is used with other spacers”.  As an 
alternative, manufacturers could verify the compatibility between 
pMDI drugs and spacer use, determine the emitted doses of 
different drugs and report these data in the “Summaries of Product 
characteristics” and “Patient information Leaflets” of all VHC for all 
pMDIs in order to facilitate prescription by the physician.  
As far as we know, ours is the first report to propose a simple 
method of testing the interference of a VHC on the emitted dose of 
all of the five most frequently used drugs respecting the breathing 
pattern of the patients rather than using mechanical filters that 
change the resistance of airflow. In this paper, the percentage of 
output in the respirable range was measured by a laser particle 
analyzer in continuous nebulization to the same point of abrupt 
drop in output. The calculation of the emitted dose proposed in this 
paper is not intended to be a simulated therapeutical dose as this 
would include patient variability, but it is nonetheless adequate to 
provide the information necessary for the Product Leaflet.  In 2007,  
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Table I. Pressurized metered dose inhaler drugs currently available on the market (nominal dose in µg/puff , without spacer), excipients and 
reference solutions. 
Drug pMDI µg/puff Excipients Reference solution (mg/mL) 
Beclomethasone 250 ethanol, glicerol 0.4 
Budesonide 200 ethanol, oleic acid 0.25 
Ciclesonide 160 ethanol not available 
Fluticasone 250 - 0.25 
Salbutamol 100 ethanol, oleic acid 5 
 
Table II. HPLC parameters applied to assay the amount of each drug. 
Drug Eluent Method V λ max 
 A B isocratic (A:B) (mL/min) (nm) 
Beclomethasone water acetonitrile 40:60 1.2 239 
Budesonide water methanol 20:80 1.5 244 
Ciclesonide water acetonitrile 10:90 1 241.7 
Fluticasone water acetonitrile 40:60 1.2 235.8 
Salbutamol water methanol Gradient 1 225 
 
 
 Table III. The Fine Particle Dose (FPD) available at the end of the spacer and the emitted dose of the drugs delivered by pMDI with or 
without the VHC (nominally released dose per actuation) 
Drug FPD ± SD (%) Amount of drug ± 
SD (μg) 
FPD Emitted dose with 
VHC 
Emitted dose without 
VHC 
% 
Beclomethasone 77 ± 6.5 117.5 ± 12.5 90.5 90.5 250 36.2 
Budesonide 91 ± 8.3 110 ± 20 100 100 200 50.0 
Ciclesonide 77 ± 4.7 133 ± 10 102 102 160 63.7 
Fluticasone 91 ± 7.7 127 ± 32 116 116 250 46.4 
Salbutamol 83 ± 8.1 65 ± 11 54 54 100 54.0 
 
Abbreviation: SD = standard deviation 
 
Mitchell et al. has already evidenced some improvements that 
might be added by manufacturers of VHC devices in order to avoid 
an inconsistent medication delivery, [21] however this lack we 
observed was not reported. 
A limit of our study is that, for technical reasons, we were only able 
to study one VHC. It would be interesting to evaluate the other 
commonly used spacers (such as AeroChamber, InspirEase and 
Volumatic) to see how much of an effect each spacer has on the 
drug output from the different pMDI-VHC systems.   
Conclusion 
When pMDIs are employed with a VHC, the emitted dose is more 
or less halved. Multiple measurements from each pMDI-VHC 
system are encouraged with the reported method in order to 
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determine how uniform and reliable the delivery of drugs is from 
each pMDI-VHC system. 
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